Publications

363 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:
  1. GVS advice setmelanotide (Imcivree®)

    The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

    Report | 08-07-2022

  2. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

    The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

    Report | 23-06-2022

  3. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 20-06-2022

  4. International strategic agenda 2022-2023 National Health Care Institute

    The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...

    Publication | 21-04-2022

  5. GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

    The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...

    Report | 24-02-2022

  6. GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

    The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

    Report | 24-02-2022

  7. GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 22-02-2022

  8. GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

    The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

    Report | 10-02-2022

  9. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

    The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

    Report | 25-01-2022

  10. Package advice tucatinib (Tukysa®)

    The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

    Report | 17-01-2022